Ever since MannKind Inc. (NASDAQ:MNKD) came into business back a couple of decades ago, the company has been looking forward to get its drugs approved from the FDA. The company made regular drugs for casual diseases but as the years went by, MannKind Inc. (NASDAQ:MNKD) started focusing upon diabetics. MannKind Inc. (NASDAQ:MNKD)’s landmark drug Afrezza treats both type 1 and 2 diabetes. Drugs made for treating diabetes have always been in demand in the market but there’s always the question of effectiveness of such drugs. The remedy to diabetes in the past was insulin, which was painful and came with various complications such as kidney failure.
MannKind Inc. (NASDAQ:MNKD)’s drug Afrezza is different from the usual insulin shot; it’s a rapid insulin shot that leaves the body quickly and comes with minimum drawbacks. The risks included in the usual shots are way higher as compared to Afrezza’s. The licensing partner of Afrezza called Sanofi announced that the drug has already started rolling out to the market. Not only that, Sanofi gave MannKind Inc. (NASDAQ:MNKD) a revenue of 150 million dollars upfront.
Now MannKind Inc. (NASDAQ:MNKD) shouldn’t really be worried about finances but what about the future of the company? Has it got any other drugs in its arsenal or is it just relying upon MannKind Inc. (NASDAQ:MNKD). The company must have some plans for the future. Also, it must be kept in mind that MannKind Inc. (NASDAQ:MNKD) must devise a strategy to keep the investors in the loop and assure them that the future is secured. The pharmaceutical boom in the industry has brought a lot of golden prospects for such companies. MannKind Inc. (NASDAQ:MNKD) will definitely benefit from this golden era of the pharmaceutical industry.
The best possible case scenario for MannKind Inc. (NASDAQ:MNKD) would be that the drug gets prescribed by doctors and makes enormous sales; enough to keep MannKind Inc. (NASDAQ:MNKD) running for the next few years without any hiccups. This will keep the investors on the ice and also the drug will be hailed as a breakthrough in dealing with Diabetes. It’s rather early to give any indications as to where MannKind Inc. (NASDAQ:MNKD) will go from here on, but the future seems bright for it because Afrezza is a drug that holds potential as compared to other diabetes related drugs.
MannKind Inc. (NASDAQ:MNKD) will be emphasizing upon keeping high end investors in the game. A company like this needs investors that stay for the longer run because pharmaceutical companies depend a lot on such investors and you never know when the industry collapses and you are left with almost nothing in your inventory. At that time, investors are the people that come to your safety, provided they are really loyal investors (which are quite rare by the way). Hopefully, MannKind Inc. (NASDAQ:MNKD) won’t have to face such situations and will grow safely and steadily. Bright days are ahead of the company.
